| Chemotherapy (6 months) | No. | |
| Folfox | 54 | |
| Xelox | 49 | |
| Post chemotherapy assessment |
| |
| CR | 95 | |
| Progression | 8 | |
| Time to progression (months) |
| |
| Min. - Max. | 3.0 - 36.0 | |
| Mean ± SD. | 13.25 ± 9.19 | |
| Median (IQR) | 12.0 (6.0 - 24.0) | |
| Toxicity | No | |
| No. | % | |
| Hand & foots syndrome | 57 | 55.3 |
| Grade 1 | 46 | 44.7% |
| Grade 2 | 0 | 0 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Neutropenia | 60 | 58.3 |
| Grade 1 | 40 | 38.8 |
| Grade 2 | 3 | 2.9 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Hepatotoxicity | 58 | 56.3 |
| Grade 1 | 45 | 43.7 |
| Grade 2 | 0 | 0 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| Neurotoxicity | 42 | 40.8 |
| Grade 1 | 29 | 28.2 |
| Grade 2 | 32 | 31.1 |
| Grade 3 | 0 | 0 |
| Grade 4 | 0 | 0 |
| GIT symptoms (diarrhea & vomiting) | ||
| Grade 1 | 25 | 24.3 |
| Grade 2 | 22 | 21.4 |
| Grade 3 | 8 | 7.8 |
| Grade 4 | 0 | 0 |